Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine- pyrimethamine and parasite resistance

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-11

  Griffin, Jamie T ^a   Cairns, Matthew ^b   Ghani, Azra C ^a   Roper, Cally ^b   Schellenberg, David ^b   Carneiro, Ilona ^b   Newman, Robert D ^c   Grobusch, Martin P ^d,e   Greenwood, Brian ^b   Chandramohan, Daniel ^b   Gosling, Roly D ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e Hôpital Albert Schweitzer   (Gabon)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; PLACEBO; ALCOHOL DEHYDROGENASE; ANTIMALARIAL AGENT; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PROTOZOAL PROTEIN; PYRIMETHAMINE; SULFADOXINE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FOLLOW UP; GENE MUTATION; HUMAN; IN VIVO STUDY; INFANT; MALARIA; MALARIA CONTROL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC ERROR; TREATMENT DURATION; TREATMENT OUTCOME; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETICS; MALARIA FALCIPARUM; MALE; METABOLISM; MUTATION; NEWBORN; NEWBORN DISEASE; PARASITOLOGY; PLASMODIUM FALCIPARUM;

ALCOHOL DEHYDROGENASE; ANTIMALARIALS; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MALARIA, FALCIPARUM; MALE; MUTATION; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 77958552838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012618     Document Type: Article

References (39)

1. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, et al. (2005) Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. Bmj 331: 727-733.
2. Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, et al. (2007) A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis 45: 16-25.
3. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, et al. (2006) Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis 194: 276-285.
4. Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, et al. (2007) Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrob Agents Chemother 51: 3273-3281.
5. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, et al. (2001) Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 357: 1471-1477.
6. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, et al. (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1521-1532.
7. Grobusch MP, Lell B, Schwarz NG, Gabor J, Dornemann J, et al. (2007) Intermittent preventive treatment against malaria in infants in Gabon-a randomized, double-blind, placebo-controlled trial. J Infect Dis 196: 1595-1602.
8. WHO (2009) Technical Consultation on Intermittent Preventive Treatment of Infants (IPTi). Geneva, Switzerland: WHO.
9. Vestergaard LS, Ringwald P (2007) Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am J Trop Med Hyg 77: 153-159.
10. Laufer MK, Djimdé AA, Plowe CV (2007) Monitoring and deterring drugresistant malaria in the era of combination therapy. Am J Trop Med Hyg 77(suppl 6): 160-169.
11. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ (1988) Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductasethymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 85: 9109-9113.
12. Peterson DS, Walliker D, Wellems TE (1988) Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 85: 9114-9118.
13. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, et al. (1994) Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 224: 397-405.
14. Triglia T, Cowman AF (1994) Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 91: 7149-7153.
15. Omar SA, Adagu IS, Warhurst DC (2001) Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 95: 315-319.
16. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380-388.
17. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, et al. (2004) Relationship between age, molecular markers, and response to sulphadoxinepyrimethamine treatment in Kampala, Uganda. Trop Med Int Health 9: 624-629.
18. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, et al. (2009) A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 8: 89.
19. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxinepyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 1533-1542.
20. Cairns M, Carneiro I, Milligan P, Owusu-Agyei S, Awine T, et al. (2008) Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. PLoS ONE 3: e2227.
21. Cairns M, Gosling R, Carneiro I, Gesase S, Mosha JF, et al. Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in tanzanian infants. PLoS One 5: e9467.
22. Ross A, Penny M, Maire N, Studer A, Carneiro I, et al. (2008) Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants. PLoS ONE 3: e2661.
23. Gosling RD, Ghani AC, Deen JL, von Seidlein L, Greenwood BM, et al. (2008) Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants? Malar J 7: 54.
24. Grobusch MP, Egan A, Gosling RD, Newman RD (2007) Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis 20: 613-620.
25. Schellenberg D, Kahigwa E, Drakeley C, Malende A, Wigayi J, et al. (2002) The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 67: 17-23.
26. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, et al. (2009) High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS ONE 4: e4569.
27. White NJ (2008) How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 7: 9.
28. May J, Adjei S, Busch W, Gabor JJ, Issifou S, et al. (2008) Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon. Malar J 7: 198.
29. Pearce RJ, Pota H, Evehe MS, Bael H, Mombo-Ngoma G, et al. (2009) Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med 6: e1000055.
30. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, et al. (2008) Emergence of a dhfr Mutation Conferring High-Level Drug Resistance in Plasmodium falciparum Populations from Southwest Uganda. J Infect Dis 197: 1598-1604.
31. Karema C, Imwong M, Fanello CI, Stepniewska K, Uwimana A, et al. Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. Antimicrob Agents Chemother 54: 477-483.
32. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, et al. (2009) Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Am J Trop Med Hyg 80: 523-527.
33. WHO (2010) WHO Policy recommendation on Intermittent Preventive Treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum Malaria control in Africa March 2010. World Health Organisation.
34. Abacassamo F, Enosse S, Aponte JJ, Gomez-Olive FX, Quinto L, et al. (2004) Efficacy of chloroquine, amodiaquine, sulphadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with noncomplicated malaria. Trop Med Int Health 9: 200-208.
35. Mayor A, Serra-Casas E, Sanz S, Aponte JJ, Macete E, et al. (2008) Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis 197: 1737-1742.
36. Oduro AR, Anyorigiya T, Hodgson A, Ansah P, Anto F, et al. (2005) A randomized comparative study of chloroquine, amodiaquine and sulphadoxinepyrimethamine for the treatment of uncomplicated malaria in Ghana. Trop Med Int Health 10: 279-284.
37. Marks F, Evans J, Meyer CG, Browne EN, Flessner C, et al. (2005) High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana. Antimicrob Agents Chemother 49: 1101-1105.
38. Mockenhaupt FP, Ehrhardt S, Dzisi SY, Teun Bousema J, Wassilew N, et al. (2005) A randomized, placebo-controlled, double-blind trial on sulfadoxinepyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 10: 512-520.
39. Mockenhaupt FP, Bousema JT, Eggelte TA, Ehrhardt S, Otchwemah RN, et al. (2005) Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana. Malar J 4: 42.